Get to know our clinical trials

Phase I/Ib dose-escalation and cohort expansion clinical trial with OMX-0407, a salt-inducible kinase inhibitor, in patients with previously treated unresectable solid tumors

THE PRIMARY OBJECTIVE OF THIS CLINICAL TRIAL IS TO DETERMINE THE SAFETY OF DIFFERENT DOSES OF OMX-0407

Imagen de la Dra. Anna Vilalta, oncóloga de la Clínica Universidad de Navarra
Dr. Anna Vilalta Lacarra [SP] Curriculum
Specialist Medical Oncology Department
Navarre headquarters
Cancer Center
Lung Cancer Area
Status
In recruitment
headquarters
Pamplona/Madrid
Early phase

Technical Summary

  • PHASE I/IB DOSE-ESCALATION AND COHORT EXTENSION STUDY WITH OMX-0407, A SALT-INDUCIBLE KINASE INHIBITOR, IN PATIENTS WITH PREVIOUSLY TREATED UNRESECTABLE SOLID TUMORS
  • Code EudraCT: 2022-002245-18
  • Protocol number: OMX-0407-101
  • Promoter: iOmx Therapeutics AG
  • Molecule/Drug: OMX-0407

* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.

More information about this clinical trial

Information offered by the Spanish Registry of Clinical Studies

  • Summary
  • Information
  • Calendar
  • Headquarters
  • Drugs
Read more about this clinical trial
Imagen de un icono azul con un fonendoscopio o estetoscopio.

Do you want to participate in this trial?

Request an appointment for our specialists to assess whether you qualify for this clinical trial

I want to make an appointment
Imagen de un icono azul de un registro en el informe médico.

Do you prefer to send us your reports?

If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.

I WANT TO REQUEST A SECOND OPINION